Biomarker Testing Patterns and Treatment Outcomes in Patients With Advanced Non-Small Cell Lung Cancer and MET Exon...

Area of Science:

• Oncology
• Genomics
• Clinical Research

Background:

• MET exon 14 skipping mutations (METex14) occur in approximately 3% of non-small cell lung cancer (NSCLC) cases.
• METex14 is an independent poor prognostic factor, associated with reduced overall and disease-specific survival.
• Broad molecular testing identifies METex14, enabling targeted therapy for advanced NSCLC (aNSCLC) patients.

Purpose of the Study:

• To examine biomarker testing patterns in aNSCLC patients with METex14.
• To evaluate clinical outcomes of chemotherapy and immuno-oncology (IO) monotherapy in this patient population.
• To assess the duration of biomarker test result reporting.

Main Methods:

• A retrospective descriptive study using the Flatiron Health-Foundation Medicine Inc. (FMI) clinico-genomic database.
• Analysis of biomarker testing (PD-L1 and FMI NGS) and time to results for aNSCLC patients with METex14.
• Kaplan-Meier estimation of real-world progression-free survival (rw-PFS) for first-line (1L) and second-line (2L) chemotherapy or IO monotherapy.

Main Results:

• 77% and 60% of eligible patients received PD-L1 and FMI NGS testing, respectively, within 3 months of diagnosis.
• Median time from specimen collection to results was 1 week shorter for PD-L1 compared to FMI NGS.
• Median 1L rw-PFS was 5.7 months for chemotherapy and 2.4 months for IO monotherapy; median 2L rw-PFS was 3.5 months for chemotherapy and 4.7 months for IO monotherapy.

Conclusions:

• Biomarker testing for METex14 and PD-L1 is common in aNSCLC, with PD-L1 testing yielding results slightly faster.
• Chemotherapy and IO monotherapy are frequently used but demonstrate limited progression-free survival in patients with METex14 aNSCLC.